vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
USANA HEALTH SCIENCES INC is the larger business by last-quarter revenue ($213.7M vs $906.0K, roughly 235.8× Mind Medicine (MindMed) Inc.). USANA HEALTH SCIENCES INC runs the higher net margin — -3.1% vs -2634.0%, a 2630.9% gap on every dollar of revenue. On growth, USANA HEALTH SCIENCES INC posted the faster year-over-year revenue change (6.7% vs -16.1%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
DFTX vs USNA — Head-to-Head
Income Statement — Q4 2023 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $213.7M |
| Net Profit | $-23.9M | $-6.5M |
| Gross Margin | — | 77.2% |
| Operating Margin | -2450.8% | 0.6% |
| Net Margin | -2634.0% | -3.1% |
| Revenue YoY | -16.1% | 6.7% |
| Net Profit YoY | -386.7% | -161.5% |
| EPS (diluted) | $-0.58 | $-0.36 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $213.7M | ||
| Q2 25 | — | $235.8M | ||
| Q1 25 | — | $249.5M | ||
| Q4 24 | — | $213.6M | ||
| Q3 24 | — | $200.2M | ||
| Q2 24 | — | $212.9M | ||
| Q1 24 | — | $227.8M | ||
| Q4 23 | $906.0K | $221.1M |
| Q3 25 | — | $-6.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $10.6M | ||
| Q2 24 | — | $10.4M | ||
| Q1 24 | — | $16.5M | ||
| Q4 23 | $-23.9M | — |
| Q3 25 | — | 77.2% | ||
| Q2 25 | — | 78.7% | ||
| Q1 25 | — | 79.0% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | 81.1% | ||
| Q1 24 | — | 81.1% | ||
| Q4 23 | — | 80.9% |
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | — | 10.8% | ||
| Q4 23 | -2450.8% | 11.0% |
| Q3 25 | — | -3.1% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 4.9% | ||
| Q1 24 | — | 7.3% | ||
| Q4 23 | -2634.0% | — |
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $0.52 | ||
| Q1 25 | — | $0.49 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | — | $0.56 | ||
| Q2 24 | — | $0.54 | ||
| Q1 24 | — | $0.86 | ||
| Q4 23 | $-0.58 | $0.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $145.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $528.1M |
| Total Assets | $124.5M | $726.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $145.3M | ||
| Q2 25 | — | $151.3M | ||
| Q1 25 | — | $179.6M | ||
| Q4 24 | — | $181.8M | ||
| Q3 24 | — | $364.9M | ||
| Q2 24 | — | $332.4M | ||
| Q1 24 | — | $328.3M | ||
| Q4 23 | $99.7M | $330.4M |
| Q3 25 | — | $528.1M | ||
| Q2 25 | — | $531.1M | ||
| Q1 25 | — | $529.8M | ||
| Q4 24 | — | $532.1M | ||
| Q3 24 | — | $533.1M | ||
| Q2 24 | — | $512.2M | ||
| Q1 24 | — | $500.0M | ||
| Q4 23 | $78.1M | $497.2M |
| Q3 25 | — | $726.6M | ||
| Q2 25 | — | $734.5M | ||
| Q1 25 | — | $746.6M | ||
| Q4 24 | — | $748.2M | ||
| Q3 24 | — | $671.3M | ||
| Q2 24 | — | $631.4M | ||
| Q1 24 | — | $629.3M | ||
| Q4 23 | $124.5M | $632.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-5.2M |
| FCF MarginFCF / Revenue | — | -2.4% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $18.7M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-2.0M | ||
| Q2 25 | — | $12.2M | ||
| Q1 25 | — | $15.5M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | — | $29.5M | ||
| Q2 24 | — | $8.0M | ||
| Q1 24 | — | $17.7M | ||
| Q4 23 | $-20.6M | $26.0M |
| Q3 25 | — | $-5.2M | ||
| Q2 25 | — | $7.2M | ||
| Q1 25 | — | $12.7M | ||
| Q4 24 | — | $4.0M | ||
| Q3 24 | — | $27.1M | ||
| Q2 24 | — | $5.3M | ||
| Q1 24 | — | $14.5M | ||
| Q4 23 | — | $18.7M |
| Q3 25 | — | -2.4% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 13.6% | ||
| Q2 24 | — | 2.5% | ||
| Q1 24 | — | 6.4% | ||
| Q4 23 | — | 8.5% |
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 1.4% | ||
| Q4 23 | — | 3.3% |
| Q3 25 | — | — | ||
| Q2 25 | — | 1.27× | ||
| Q1 25 | — | 1.65× | ||
| Q4 24 | — | 1.29× | ||
| Q3 24 | — | 2.78× | ||
| Q2 24 | — | 0.77× | ||
| Q1 24 | — | 1.07× | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DFTX
Segment breakdown not available.
USNA
| Direct Selling | $175.8M | 82% |
| Hiya | $30.8M | 14% |
| All Other | $7.0M | 3% |
